Alzheimer’s disease biological PET staging using plasma p217+tau
Abstract Background Plasma phospho-tau biomarkers, such as p217+tau, excel at identifying Alzheimer’s disease (AD) neuropathology. However, their ability to substitute for tau PET to identify AD biological stage is unclear. Methods Participants included 248 cognitively unimpaired (CU) and 227 cognit...
Saved in:
| Main Authors: | Azadeh Feizpour, Vincent Doré, Natasha Krishnadas, Pierrick Bourgeat, James D. Doecke, Ziad S. Saad, Gallen Triana-Baltzer, Simon M. Laws, Rosita Shishegar, Kun Huang, Christopher Fowler, Larry Ward, Colin L. Masters, Jurgen Fripp, Hartmuth C. Kolb, Victor L. Villemagne, Christopher C. Rowe |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-025-00768-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platformResearch in context
by: Azadeh Feizpour, et al.
Published: (2024-11-01) -
Identification of late-stage tau accumulation using plasma phospho-tau217Research in context
by: Marcel S. Woo, et al.
Published: (2024-11-01) -
Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
by: Divya Bali, et al.
Published: (2025-06-01) -
Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
by: David Wilson, et al.
Published: (2025-07-01) -
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)